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Abstract 
Background: Trauma-induced coagulopathy in patients with traumatic brain injury (TBI) is associated with high 
rates of complications, unfavourable outcomes and mortality. The mechanism of the development of TBI-associated 
coagulopathy is poorly understood.
Methods: This analysis, embedded in the prospective, multi-centred,observational Collaborative European Neuro-
Trauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study, aimed to characterise the coagulopathy of 
TBI. Emphasis was placed on the acute phase following TBI, primary on subgroups of patients with abnormal coagula-
tion profile within 4 h of admission, and the impact of pre-injury anticoagulant and/or antiplatelet therapy. In order to 
minimise confounding factors, patients with isolated TBI (iTBI) (n = 598) were selected for this analysis.
Results: Haemostatic disorders were observed in approximately 20% of iTBI patients. In a subgroup analysis, patients 
with pre-injury anticoagulant and/or antiplatelet therapy had a twice exacerbated coagulation profile as likely as 
those without premedication. This was in turn associated with increased rates of mortality and unfavourable outcome 
post-injury. A multivariate analysis of iTBI patients without pre-injury anticoagulant therapy identified several inde-
pendent risk factors for coagulopathy which were present at hospital admission. Glasgow Coma Scale (GCS) less than 
or equal to 8, base excess (BE) less than or equal to − 6, hypothermia and hypotension increased risk significantly.
Conclusion: Consideration of these factors enables early prediction and risk stratification of acute coagulopathy after 
TBI, thus guiding clinical management.
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Introduction
Traumatic brain injury (TBI) remains a leading cause of 
death and disability worldwide [1]. The initial insult often 
results in disruptions of the cerebral vasculature and 
pathological alterations of the blood–brain barrier (BBB) 
which may evolve into haemorrhagic lesions. In addition, 
TBI-associated factors may disturb the body’s haemoco-
agulative capacity and alter the delicate balance between 
bleeding and thrombus formation leading to a substantial 
exacerbation of the initial injury sustained [2–5]. Recent 
evidence suggests that the acute phase after TBI is rather 
characterised by dysfunction of the coagulation cascade 
and hyperfibrinolysis, both of which likely contribute to 
haemorrhagic progression. This may then be followed 
by platelet dysfunction and decreased platelet count 
while the clinical implication of these alterations remains 
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unclear. At later stages, a poorly defined prothrombotic 
state emerges, partly due to fibrinolysis shutdown and 
hyperactive platelets [6–8]. Haemostatic alterations, 
in particular those during the acute phase after TBI, 
have been associated with higher mortality and more 
unfavourable outcome than in non-coagulopathic TBI 
patients [2, 4, 9–11].
The present study aimed to further characterise the 
alterations to the haemostatic system occurring in the 
context of isolated TBI (iTBI) based upon data collected 
into the central database (INCF Neurobot tool version 
2.0 (INCF, Stockholm, Sweden) of the prospective, multi-
centred, observational Collaborative European Neuro-
Trauma Effectiveness Research in Traumatic Brain Injury 
(CENTER-TBI) cohort study. Particular interest was 
given to the impact of pre-injury anticoagulant and/or 
antiplatelet therapy. Risk stratification was performed to 




The present study was an embedded study to the longitu-
dinal, observational CENTER-TBI study, which recruited 
patients from 60 selected centres across Europe and 
Israel between December 2014 and December 2017 [12]. 
A total of 4509 patients with a clinical diagnosis of TBI 
were included in the CENTER-TBI core database. Inclu-
sion criteria were a clinical diagnosis of TBI, indication 
for CT scanning, presentation to study centre within 
24  h of injury, and informed consent obtained accord-
ing to local and national requirements [12]. Participants 
were excluded if they had any severe pre-existing neu-
rological disorder that could have confounded outcome 
assessments. As part of the CENTER-TBI core study, 
the present analysis was performed in accordance with 
all relevant local and European laws. Informed consent, 
including the approval to use data for research purposes, 
was obtained from each subject according to local ethics 
and regulations.
Patients with extracranial injuries, defined as 
 AISExtracranial > 0, and those missing critical data points 
were excluded a priori. We included patients for whom 
data reporting conventional coagulation parameters 
within 4 h following iTBI were available. This population 
included subgroups that developed laboratory abnor-
malities and those with pre-injury anticoagulant and/or 
antiplatelet therapy.
Data Collection
The cohort included patients with iTBI who were char-
acterised with respect to the presence of haemostatic 
abnormalities based upon conventional coagulation 
parameters within 4  h of injury. The prospectively 
recorded parameters in scope of the CENTER-TBI core 
study that were considered for analysis comprised demo-
graphics, injury characteristics, medical history, medical 
presentation in the emergency department (ED), admis-
sion laboratory values and pre-injury anticoagulant and/
or antiplatelet therapy. Follow-up data on functional 
outcome, including mortality and Glasgow Outcome 
Score-Extended (GOS-E), were obtained 6-month post-
injury. A GOS-E between 1 and 4 (dead, vegetative state, 
low severe and upper severe disability) was considered 
unfavourable.
The primary outcome as the presence or absence of 
abnormal coagulation profile was defined by conventional 
coagulation parameters obtained within 4 h of the injury. 
The following parameters were considered for diagnosing 
an abnormal coagulation profile: International Normal-
ised Ratio (INR) > 1.2 or activated partial thromboplastin 
time (aPTT) > 35  s or fibrinogen < 150 mg/dL or platelet 
count < 100 × 103/nL. All relevant data for further analy-
sis were extracted from the INCF Neurobot tool version 
2.0 (INCF, Stockholm, Sweden).
Statistical Analysis
For the descriptive analysis of iTBI patients with and 
without pre-injury anticoagulant and/or antiplatelet 
therapy, metric data are presented as median and inter-
quartile range (IQR). Categorical data are presented in 
percentage. Differences were tested using the Mann–
Whitney U test and Chi-squared  (Chi2) test, respectively. 
Nonparametric Kruskal–Wallis test was performed to 
compare the standard coagulation test in relation to 
injury severity  (AISBrain) in iTBI. A p value < 0.05 was 
considered statistically significant.
In a univariate analysis, potential predictors for an 
abnormal coagulation profile were identified via  Chi2 
test. A logistic regression analysis (multivariate analy-
sis) with coagulopathy as dependent variable was per-
formed to evaluate independent risk factors associated 
with acute coagulopathy in iTBI. Analysis of potential 
predictors and independent risk factors of iTBI patients 
with pre-injury anticoagulant and/or antiplatelet therapy 
was not feasible due to the low number of cases. Some 
predictors were discriminated as independent risk fac-
tors (e.g. age ≥ 75, sex, neuroworsening) as no differences 
were detected. The predictor “arrival haemoglobin” was 
excluded due to low prevalence. The results are pre-
sented as odds ratio (OR) with 95% confidence interval 
 (Cl95) and regression coefficient. Statistical analyses were 
performed using SPSS statistics version 25 for Windows 
(IBM Corp., Armonk, NY, USA) and GraphPadPrism ver-
sion 7.00 (GraphPad Software, La Jolla California, USA).
Results
Cohort Characteristics
From the 4509 patients included into the CENTER-TBI 
core study database, 3287 had to be excluded for co-
existing extracranial injuries and 624 for missing data 
(Fig.  1). Thus, 598 patients with iTBI were included in 
the present analysis. Approximately one-fifth of the 
cohort was assigned to the group of elderly patients 
(≥ 75 years, Table 1). Almost all patients (98.7%, data not 
shown) had sustained a blunt trauma mechanism result-
ing from various injury patterns, with ground-level falls 
being the most common cause of injury (28.3%, data 
not shown). The majority of the injuries sustained were 
severe  (AISBrain ≥ 3, 85%, Table  1) and closed head inju-
ries (93.5%, Table 1). Computed tomography (CT) scans 
performed immediately after emergency department 
(ED) admission revealed the following most frequent 
intracranial pathologies: (1) subarachnoid haemorrhage 
(52%), (2) subdural haematoma (46.4%), (3) midline shift 
(24.9%), (4) extradural haematoma (16.5%), (5) basal cis-
tern compression (13.5%), (6) depressed skull fracture 
(13.2%) and (7) diffuse axonal injury (9.2%) (data not 
shown).
Haemostatic alterations based upon conventional coag-
ulation parameters within 4 h after injury were present in 
19.6% of included iTBI patients (n = 117/598, Table 1). In 
addition, for one in five patients pre-injury anticoagulant 
and/or antiplatelet therapy was documented (Table  1). 
Ninety-eight iTBI patients (16.4%, Table 1) died while the 
Fig. 1 Schematic overview of CENTER-TBI cohort with inclusion and exclusion process for the present subgroup
median outcome in surviving patients at 6 months after 
iTBI was favourable (Table 1).
Subgroup Analysis of Patients with Pre‑injury Antiplatelet 
and/or Anticoagulant Therapy
Patients with pre-injury anticoagulant and/or antiplate-
let therapy were significantly older than those without. 
The proportion of patients ≥ 75 years of age comprised 
more than half in the group of patients on pre-injury 
anticoagulant and/or antiplatelet therapy (Table  2). A 
greater proportion of patients with pre-injury anticoag-
ulant and/or antiplatelet medication had an untreatable 
TBI defined as  AISBrain = 6. Coagulopathy by conven-
tional coagulation parameters was diagnosed twice as 
frequently in patients on pre-injury anticoagulant and/
or antiplatelet therapy (Table  2). Conventional coagu-
lation parameters such as INR and aPTT were sig-
nificantly deteriorated and platelet counts trended to 
decrease among patients with pre-injury anticoagu-
lation and/or antiplatelet therapy (Table  2). In those 
patients without pre-injury anticoagulant therapy, con-
ventional coagulation parameters significantly deterio-
rated with increasing severity of brain injury; a higher 
 AISBrain correlated with higher INR, lower fibrinogen 
levels and lower platelet counts (Fig.  2). Patients with 
iTBI and on pre-injury anticoagulant and/or anti-
platelet therapy had threefold higher mortality and 
higher frequency of unfavourable 6-month outcomes 
(GOS-E 1–4) compared to those without pre-injury 
anticoagulant and/or antiplatelet therapy (51.9% vs. 
23.5%) (Table 2, Fig. 3). Notably, a higher percentage of 
patients with pre-injury intake of vitamin K antagonists 
had an abnormal coagulation profile after iTBI than 
patients on other pre-injury anticoagulant or antiplate-
let therapy (Table 3).
Risk Factors for Coagulopathy of Patients Without 
Pre‑injury Antiplatelet and/or Anticoagulant Therapy
Univariate analysis identified higher magnitude of brain 
injury  (AISBrain) (p = 0.001) and lower GCS on admis-
sion as potential independent risk factors (p < 0.001) for 
an acute coagulopathy (Table  4). Patients with coagu-
lopathy were three times as likely to have unreactive 
pupils than non-coagulopathic patients with (Table 4). 
Coagulopathic patients were three times more likely to 
be hypoxic (patients with a  PaO2 < 8  kPa (60  mmHg) 
and/or a  SaO2 < 90%), eight times more likely to be 
hypotensive and more than five times more likely to be 
hypothermic (Table 4). Altered base excess (BE) (≤ − 6) 
occurred 5.7 times more frequently in coagulopathic 
patients (Table  4). Severe intracranial lesions causing 
basal cistern compression and severe contusions were 
associated with coagulopathy,with 2.5- and 2.4-fold 
increased incidence, respectively, among coagulopathic 
patients (Table  4). Mortality among coagulopathic 
patients with iTBI was almost three times higher than 
those with normal coagulation profile (25.3% vs. 9.0%; 
p < 0.0001) (data not shown). Multivariate regression 
analysis identified significant independent risk factors 
associated with coagulopathy in iTBI patients includ-
ing odds ratios (OR): the GCS ≤ 8 at hospital admission 
had an OR of 2.4 and unbalanced BE (≤ − 6) had an 
OR of 3.1 (Table 5). Systemic secondary insults such as 
hypotension (< 90 mmHg SBP), which had an OR of 3.5 
and hypothermia (temperature < 35  °C), with an OR of 
2.9, were also identified (Table 5).
Table 1 Characteristics of patients with isolated traumatic 
brain injury < 4 h following injury (n = 598)
AIS Abbreviated Injury Scale, aPTT activated partial thromboplastin time, ED 
Emergency department, GCS Glasgow Coma Scale, GOS-E Glasgow Outcome 
Score-Extended, INR International Normalized Ratio, SBP Systolic blood pressure
iTBI patients n = 598
Demographics
 Age, years; median [IQR] 52 [30–69]
 Age ≥ 75; n [%] 106 [17.7]
 Male gender; n [%] 415 [69.4]
Injury characteristics
 Closed TBI; n [%] 559 [93.5]
 AISBrain 2; n [%] 71 [11.9]
 AISBrain 3; n [%] 205 [34.3]
 AISBrain 4; n [%] 158 [26.4]
 AISBrain 5; n [%] 147 [24.6]
 AISBrain 6; n [%] 17 [2.8]
Medical presentation at admission (ED)
 GCS; median [IQR] 14 [10–15]
 SBP; mmHg; median [IQR] 138 [121–156]
 Heart rate; bpm; median [IQR] 80.0 [70.5–95.0]
 Temperature;  °C; median [IQR] 36.2 [35.8–36.7]
 Received emergency surgical intervention; n 
[%]
119 [19.9]
Coagulation status, tests and medications
 Coagulopathy; n [%] 117 [19.6]
 Haemoglobin; g/dl; median [IQR] 13.7 [12.6–14.7]
 INR; median [IQR] 1.04 [1.00–1.15]
 aPTT; seconds; median [IQR] 28.2 [25.1–32.4]
 Platelets;/nl; median [IQR] 224 [183–267.5]
 Fibrinogen; mg/dl; median [IQR] 274.5 [230–320]




 Death [overall]; n [%] 98 [16.4]
 GOS-E [6 months—derived]; median [IQR] 7 [3–8]
In contrast to the univariate analysis (p = 0.016), 
hypoxia could not be identified as a risk factor in the 
multivariate analysis (p = 0.138) (Table  4, Table  5). 
However, hypoxia was only documented in 20 iTBI 
patients.
Discussion
The characterisation of haemostatic abnormalities 
which occur in the context of isolated TBI informs our 
knowledge and may promote a more effective clini-
cal risk assessment and management during the early 
course after trauma. The cohort analysed in the present 
study had a median age of 52 years, with almost one out 
of five patients being 75 years of age or older. For over 
20% of the cohort pre-injury anticoagulant and/or anti-
platelet agents, intake was documented. The mortality 
of the entire iTBI cohort was 16.4% and almost every 
fifth patient required an emergency surgical interven-
tion. Overall, the presence of coagulopathy in the acute 
phase of iTBI based upon conventional coagulation 
parameters was observed in about 20% of all patients 
with iTBI. In previous reports, the prevalence of coagu-
lopathy in TBI patients with and without extracranial 
injuries patients upon hospital admission was variable 
ranging from 7 to 63% [5]. The reported prevalence in 
all cases was highly dependent on how both TBI and 
coagulopathy were defined, the sensitivity of the coagu-
lation assays used, the time point after injury at which 
the coagulation system was assessed and the range 
of injury severity [9, 13–16]. We used conventional 
coagulation plasma based assays to assess the degree 
of coagulopathy in our cohort. However, prothrombin 
time and aPTT assays only provide a rather incomplete 
assessment of a patient’s current haemostatic capacity 
Table 2 Characteristics of iTBI patients with and without pre-injury anticoagulation therapy (n = 598)
Data on the presence of pre-injury anticoagulation therapy were missing in one case
AIS Abbreviated Injury Scale, aPTT activated partial thromboplastin time, ED Emergency department, GCS Glasgow Coma Scale, GOS-E Glasgow Outcome Score-
Extended, INR International Normalized Ratio, SBP Systolic blood pressure
iTBI patients without pre‑injury anti‑
platelet and/or anticoagulant therapy 
n = 475
iTBI patients with pre‑injury anti‑




 Age; years; median [IQR], 44 [25–61] 75 [68–81] < 0.001
 Age ≥ 75; n [%] 42 [8.8] 64 [52.5] < 0.001
 Male gender; n [%] 333 [70.1] 82 [67.2] 0.536
Injury characteristics
 Closed TBI; n [%] 443 [93.2] 115 [94.2] 0.690
 AISBrain 2; n [%] 55 [11.5] 16 [13.1] 0.640
 AISBrain 3; n [%] 164 [34.5] 41 [33.6] 0.849
 AISBrain 4; n [%] 130 [27.4] 28 [23.0] 0.324
 AISBrain 5; n [%] 118 [24.8] 28 [23.0] 0.665
 AISBrain 6; n [%] 8 [1.7] 9 [7.4] 0.001
Medical presentation at admission (ED)
 GCS; median [IQR] 14 [11–15] 14 [9–15] 0.747
 SBP; mmHg; median [IQR] 135 [120–150] 150 [132.5–169.2] < 0.001
 Heart rate; bpm; median [IQR] 80 [72–95] 80 [67.8–92.3] 0.368
 Temperature;  °C; median [IQR] 36.2 [35.8–36.7] 36.3 [35.8–36.7] 0.581
 Received emergency surgical intervention; n [%] 97 [20.4] 21 [17.2] 0.427
Coagulopathy, standard laboratory
 Coagulopathy; n [%] 75 [15.8] 42 [34.4] < 0.001
 Haemoglobin; g/dl; median [IQR] 13.9 [12.7–14.8] 13.7 [12.7–14.9] 0.993
 INR; median [IQR] 1.03 [1.0–1.1] 1.1 [1.0–2.48] < 0.001
 aPTT; seconds; median [IQR] 28.0 [25.0–32.0] 29.2 [26.0–35.0] 0.007
 Platelets;/nl; median [IQR] 226 [183–272] 214 [185–254] 0.052
 Fibrinogen; mg/dl; median [IQR] 270 [230–316.5] 304 [251.7–380] 0.018
Outcomes
 Death [overall]; n [%] 55 [11.6] 43 [35.2] < 0.001
 GOS-E [6 months—derived]; median [IQR] 7 [5–8] 4 [1–8] < 0.001
[17]. Although viscoelastic testing, such as TEG and 
ROTEM, allows a more detailed analysis of the coagula-
tion system in time, data based on this technology were 
only available in a small proportion of iTBI patients 
from the CENTER-TBI study core documentation, 
thus precluding meaningful analysis. For this reason, 
the conventional parameters INR, aPTT and platelet 
count were used as primary outcome marker indicating 
coagulopathy using the thresholds based upon previous 
studies [5, 18, 19].
The frequency of haemostatic alterations which 
occur in the context of iTBI may increase with injury 
severity [5, 9]. In the present study,  AISBrain was not 
an independent predictor of coagulopathy; however, a 
larger proportion of patients with severe head injury 
 (AISBrain ≥ 5) displayed alterations as compared to 
those with lower magnitudes sustained. Coagulopa-
thy has previously been reported more frequently in 
penetrating than in blunt brain injuries [9, 19, 20]. In 
Fig. 2 Conventional coagulation parameters INR (a), fibrinogen level (b) aPTT (c) and platelet count (d) in relation to injury severity  (AISBrain) of 
iTBI patients (n = 475). One patient with  AISBrain = 6 was excluded from the analysis. Statistically significant differences are marked with asterisks 
(*p < 0.05, **p < 0.001, ***p < 0.0001)
Fig. 3 Incidence of mortality and unfavourable Glasgow Outcome 
Score-Extended (GOS-E) (1–4) 6-month post-injury in iTBI patients 
with no pre-injury anticoagulation therapy (n = 475) versus patients 
with pre-injury anticoagulation therapy (n = 122)
the present study, less than 2% of iTBI patients had 
sustained a penetrating injury mechanism. Therefore, 
the prevalence of coagulopathy reported corresponds 
rather to its prevalence in the context of a blunt injury 
mechanism.
Previous reports indicated that coagulopathic TBI 
patients had a nine times higher mortality and 30 times 
higher risk of unfavourable outcome compared to non-
coagulopathic TBI patients [2, 9]. In the present cohort, 
a significant increase in mortality among coagulopathic 
iTBI patients (25.3%) compared to non-coagulopathic 
patients (9.0%) was observed. A retrospective study 
based upon a large dataset from trauma patients includ-
ing those with TBI revealed that patients with blunt TBI 
showing at least one abnormality in their coagulation 
profile had a higher mortality rate than non-coagulo-
pathic TBI patients [20]. In line with these findings, the 
coagulation parameters of iTBI patients in the present 
study without pre-injury anticoagulant and/or antiplate-
let therapy were significantly deteriorated with increasing 
severity of brain injury, e.g. the higher the  AISBrain, the 
higher the INR and the lower the fibrinogen levels and 
platelet counts.
Anticoagulant and antiplatelet agents appear to worsen 
outcome in iTBI. For every fifth iTBI patient in the pre-
sent study (n = 122), pre-injury intake of anticoagulant 
and/or antiplatelet agents was documented. Anticoagu-
lant and/or antiplatelet drugs are increasingly prescribed 
for several indications in the elderly [21]. Vice versa, 
epidemiological studies have confirmed that the highest 
incidence of TBI occurs in older adults with falls as the 
most common mechanism leading to severe head inju-
ries [22–24]. In particular, patients with pre-injury anti-
coagulant and/or antiplatelet drugs are at increased risk 
of developing a progressive haemorrhagic injury follow-
ing a traumatic intracranial haemorrhage [5, 25–29]. In 
the present study, elderly iTBI patients with pre-injury 
anticoagulant and/or antiplatelet drugs had an almost 
twofold increased risk to establish haemostatic abnor-
malities than those without this risk factor (34% vs. 16%). 
It is conceivable that the increased haemostatic alteration 
risk in geriatric TBI patients is associated with pre-injury 
anticoagulant and/or antiplatelet therapy. In the present 
study, iTBI patients with pre-injury medication of vita-
min K antagonists displayed a higher risk to develop an 
abnormal coagulation profile compared to those with 
other pre-injury anticoagulant and/or antiplatelet ther-
apy. Most likely, these patients have an exacerbated pro-
gress of TBI, severe complications and outcome due to 
their pre-existing with vitamin K antagonists. In line with 
these findings, retrospective studies described higher 
prevalence of spontaneous bleeding rates and worse 
outcome in elderly, vitamin K-antagonist treated iTBI 
patients compared to other anticoagulant agents and 
platelet inhibitors [30–32]. Despite both groups having 
a median  AISBrain = 4, haemostatic alteration was much 
more common among anticoagulated patients. If the risk 
factors for coagulopathy in iTBI patients with pre-injury 
anticoagulant and/or antiplatelet drugs were similar to 
those not on these drugs remain speculative due to the 
limited numbers of patients in these subgroups preclud-
ing a meaningful analysis. The overall outcomes among 
elderly iTBI patients on pre-injury anticoagulant and/or 
antiplatelet drugs in the present study were significantly 
worse compared to iTBI patients without anticoagulation 
therapy (mortality 35.2% in anticoagulated patients vs. 
11.6% in non-anticoagulated patients).
Table 3 Overview of pre-injury anticoagulant and/or antiplatelet therapy in iTBI patients (n = 122)
Anticoagulants were defined as Vitamin K antagonist (Coumarin derivates Coumadin or Warfarin), direct oral anticoagulants (Factor Xa inhibitor (e.g. Xarelto, 
Rivaroxaban), direct thrombin inhibitors (e.g. Dabigatran) and antithrombin protein inhibitor (e.g. ATryn). Platelet inhibitors mainly included acetylsalicylic acid 
(ASS). Patient specified with “Other” received platelet aggregation inhibitor such as Clopidogrel or Parasugrel. Data about specific pre-injury antiplatelet and/or 
anticoagulant therapy were missing for one case
*Patients with dual platelet inhibitor therapy
iTBI patients with pre‑injury antiplatelet and/or anticoagulant 





 Vitamin K antagonists 37 31 [84]
 Heparin 2 1 [50]
 Direct oral anticoagulants (DOACs) 12 2 [17]
 Other anticoagulants 4 1 [25]
Platelet inhibitors
 ASS 43 4 [9]
 Other platelet inhibitors* 23 3 [13]
Clinical data from prospective observational stud-
ies and meta-analyses on TBI patients have been used 
to describe factors that characterise the development of 
TBI-associated coagulopathy [2, 20, 33, 34]. The results 
of both uni- and multivariate analyses obtained from 
the present study identified hypotension, deranged BE, 
hypothermia, low GCS and hypoxia being associated 
with coagulopathy in iTBI patients. With an odds ratio of 
3.51, hypotension was the most strongly associated risk 
factor identified. The results from an earlier prospective 
study showed that iTBI patients only developed a coag-
ulopathy in the presence of a hypotension, regardless of 
head injury severity [35]. A base excess ≤ − 6 suggests 
tissue hypoperfusion most likely to result from systemic 
hypotension which had an odds ratio of 3.11 indicating 
coagulopathy. Hypothermia was further identified as 
an associated risk factor for acute coagulopathy follow-
ing iTBI with OR of 2.89. In previous studies of trauma 
patients, hypothermia has been a risk factor for mortality 
but not directly for coagulopathy [36, 37]. Hypothermia 
induces coagulopathy by causing deterioration of plate-
let function, reducing activity of coagulation factors and 
reducing fibrinogen synthesis all together with increased 
morbidity and mortality [38–40]. Hypoxia plays an 
Table 4 Univariate analysis of potential risk factors associated with acute coagulopathy following iTBI of patients with-
out pre-injury antiplatelet and/or anticoagulant therapy (n = 475)
Systemic secondary insult parameters pre-hospital/at hospital admission were defined as following: hypotension with systolic blood pressure (SBP) < 90 mmHg, 
hypothermia with temperature < 35 °C and hypoxia with a  PaO2 < 8 kPa (60 mmHg) and/or a  SaO2 < 90%. Neuroworsening was defined as follows: (1) a decrease in GCS 
motor score of 2 or more points; (2) a new loss of pupillary reactivity or development of pupillary asymmetry ≥ 2 mm; (3) deterioration in neurological or CT status 
sufficient to warrant immediate medical or surgical intervention
AIS Abbreviated Injury Scale, CT computed tomography, ED Emergency department, GCS Glasgow Coma Scale
No coagulopathy n = 400 Coagulopathy n = 75 p value
Demographics
 Age ≥ 75; n [%] 38 [9.5] 4 [5.3] 0.243
 Male gender; n [%] 283 [70.8] 50 [66.7] 0.478
Injury characteristics
 AISBrain severity 0.001
 AIS 2; n [%] 50 [12.5] 5 [6.7]
 AIS 3; n [%] 143 [35.8] 21 [28.0]
 AIS 4; n [%] 115 [28.7] 15 [20.0]
 AIS ≥ 5; n [%] 92 [23.0] 34 [45.3]
Medical presentation at admission (ED)
 GCS on admission < 0.001
 GCS ≥ 8; n [%] 249 [62.3] 25 [33.3]
 GCS ≤ 8; n [%] 49 [12.3] 22 [29.3]
 GCS unknown; n [%] 102 [25.5] 28 [37.3]
 Pupils [uni- or bilateral unreactive]; n [%] 29 [7.2] 17 [22.7] < 0.001
 Hypoxia; n [%] 13 [3.3] 7 [9.3] 0.016
 Hypotension; n [%] 6 [1.5] 9 [12.0] < 0.001
 Hypothermia; n [%] 10 [2.5] 10 [13.3] < 0.001
 Neuroworsening; n [%] 48 [12.0] 8 [10.7] 0.742
Laboratory tests
 Arrival haemoglobin < 11; n [%] 16 [4.0] 3 [4.0] 0.742
 Arrival Base Excess ≤ − 6; n [%] 16 [4.0] 17 [22.7] < 0.001
Injuries identified on initial CT scan
 Diffuse axonal injury; n [%] 39 [10.2] 10 [14.1] 0.338
 Extradural haematoma; n [%] 77 [19.5] 11 [14.7] 0.321
 Subdural haematoma; n [%] 160 [40.4] 37 [49.3] 0.151
 Subarachnoid haemorrhage; n [%] 208 [52.4] 43 [57.3] 0.432
 Midline shift; n [%] 77 [19.6] 22 [29.3] 0.058
 Basal cistern compression; n [%] 40 [10.2] 19 [25.3] < 0.001
 Depressed skull fracture; n [%] 52 [13.1] 15 [20.0] 0.116
 Severe contusion; n [%] 22 [5.6] 10 [13.3] 0.016
important role in worsening outcome in TBI as it may 
cause cerebral inflammation and the release of cytokines, 
augmenting further secondary brain injury [41, 42]. In 
the present study, hypoxia was identified as another risk 
factor indicating coagulopathy and poor outcome follow-
ing iTBI (OR 2.09). In contrast to the univariate analysis 
(p = 0.016), hypoxia could not be statistically identified 
as risk factor in the multivariate analysis (p = 0.138). 
The difference in p values was marginal but exceeded 
p = 0.05. On the one hand, the variance of p values in 
the multivariate model was probably attenuated by cor-
relation with other variables, hereby changing the effects 
(odds ratios) and p values of the other predictors. Thus, it 
may be that hypoxic patients showed other physical find-
ings that may be captured in the model, so that the effect 
may differ from the univariate effect. On the other hand, 
hypoxia was observed in only 20 patients providing a fur-
ther limitation leading to increased p values. Neverthe-
less, we consider that hypoxia is indeed a risk factor for 
coagulopathy, with an odds ratio of 2.09, but our data are 
not sufficient to prove this with 95% certainty.
Last but not least, GCS ≤ 8 at hospital admission was 
identified as an independent risk factor for acute coag-
ulopathy in iTBI patients in this study. Other studies 
which have linked altered GCS with coagulopathy have 
proposed that injury to the brain itself may induce coagu-
lation disturbances [5, 20, 43]. In a multivariate analysis 
of iTBI patients from the German Trauma Registry (TR-
DGU®), a low GCS (≤ 8) was identified as an independ-
ent risk factor for coagulopathy after TBI [20]. It was 
also concluded that a lower GCS may correlate with a 
higher risk of neurological decline in iTBI patients with 
coagulopathy [20]. Related to the identified risk fac-
tors, we cannot exclude volume substitution as well as 
receipt of blood products or haemostatic agents during 
early prehospital care as a potential cofounder that may 
have altered haemostatic capacity in the severely injured 
patients, as a prehospital data collection was not part of 
the CENTER-TBI core study. Likewise, early in-hospital 
blood product administration prior to any laboratory 
coagulation testing was marginally evaluated and pre-
cluded a more detailed analysis at this stage. The pre-
dictors identified in this study could be used in clinical 
settings to identify high-risk patients earlier. The results 
could also support in defining the course and the severity 
of coagulopathy following iTBI.
Table 5 Independent risk factors associated with acute coagulopathy in iTBI of patients without pre-injury antiplatelet 
and/or anticoagulant therapy (n = 475)
Systemic secondary insult parameters pre-hospital/at hospital admission were defined as following: hypotension with systolic blood pressure (SBP) < 90 mmHg, 
hypothermia with temperature < 35 °C and hypoxia with a  PaO2 < 8 kPa (60 mmHg) and/or a  SaO2 < 90%. In nine cases, data were missing for multivariate analysis
AIS Abbreviated Injury Scale, CT computed tomography, ED Emergency department, GCS Glasgow Coma Scale
Regression coefficient Odds ratio  (CI95) p value
Injury characteristics
 AISBrain severity
 AIS 3; n [%] 0.21 1.02 [0.45-2.31] 0.961
 AIS 4; n [%] − 0.52 0.59 [0.23–1.49] 0.267
 AIS ≥ 5; n [%] − 0.18 0.83 [0.30–2.29] 0.721
Medical presentation at admission (ED)
 GCS on admission
 GCS ≤ 8; n [%] 0.86 2.37 [1.20–4.69] 0.013
 GCS unknown; n [%] 0.45 1.57 [0.87–2.85] 0.133
 Pupils [uni- or bilateral unreactive]; n [%] 0.47 1.59 [0.78–3.24] 0.197
 Hypoxia; n [%] 0.74 2.09 [0.79–5.57] 0.138
 Hypotension; n [%] 1.25 3.51 [1.25–9.83] 0.017
 Hypothermia; n [%] 1.06 2.89 [1.11–7.58] 0.030
Laboratory test
 Arrival base excess ≤ − 6; n [%] 1.13 3.11 [1.33–7.26] 0.009
 No arrival base excess ≤ − 6; n [%] − 0.92 0.91 [0.54–1.53] 0.729
Injuries identified on initial CT scan
 Midline shift; n [%] 0.50 1.65 [0.94–2.90] 0.830
 Basal cistern compression; n [%] − 0.009 0.99 [0.49–2.01] 0.980
 Depressed skull fracture; n [%] − 0.004 0.99 [0.51–1.93] 0.991
 Severe contusion; n [%] 0.24 1.27 [0.56–2.89] 0.558
Limitations
The present study is the first report on haemostatic 
alterations occurring in the context of iTBI based upon 
data from the longitudinal, observational CENTER-TBI 
core study cohort. The results confirm previous findings 
on demographics, clinical presentation and coagulation 
status during the acute phase, e.g. within 4 h, after iTBI. 
Future analyses will now more thoroughly investigate the 
coagulation abnormalities encountered in this unique 
and highly detailed patient dataset. The limitations to the 
given study apart from those inherent to retrospective 
analysis of a large prospectively collected dataset include 
that the recruitment to the CENTER-TBI core study was 
not consecutive and was determined by site logistics 
and research interests. This means that patient selection 
bias may be possible. Likewise, coagulation parameters 
beyond those used for conventional testing, in particular 
those potentially reflecting functional deficits, were only 
marginally captured and precluded more in-depth analy-
sis at this stage. This also refers to the completeness of 
the datasets analysed as data collection was performed 
over 4  years. However, among variables considered for 
this analysis, there was little missing data. The reported 
associations remain purely descriptive. It can certainly 
not be concluded from the present analysis whether the 
observed coagulopathy was the result of the iTBI itself 
or the precipitating factor that led to a worsening of the 
clinical situation along with iTBI.
Conclusion
The prevalence of coagulopathy in iTBI patients on pre-
injury anticoagulant and/or antiplatelet therapy was sig-
nificantly higher than in patients without anticoagulant 
therapy. Independent risk factors associated with acute 
coagulopathy in iTBI included systolic hypotension, base 
excess, hypothermia, reduced GCS on ED admission 
and hypoxia. The acknowledgement and assessment of 
these risk factors could be helpful in clinical practice for 
the early identification of TBI-associated coagulopathy, 
resulting in the expeditious provision of appropriate, tar-
geted clinical management. It remains to be determined 
whether to coagulopathy seen was the result of the iTBI 
itself or a precipitating factor for neuroworsening.
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